Topic
Diabetes management
About: Diabetes management is a research topic. Over the lifetime, 6060 publications have been published within this topic receiving 164670 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Inpatient diabetes management (IDMET) substantially improved glycemic control 1 year after discharge in patients newly discharged on insulin; patients previously treated with insulin did not benefit.
73 citations
••
01 Jul 2006TL;DR: Exenatide is the first drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus and may provide advantages over adding insulin to a sulfonylurea or metformin.
Abstract: Exenatide is the first drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus. Although structurally similar to the native glucagon-like peptide, this synthetic form has a much longer duration of action. Randomized trials have shown exenatide to be efficacious in improving glycemic control when combined with either metformin or a sulfonylurea. The dose is initially 5 mcg subcutaneously twice daily and may be titrated to 10 mcg subcutaneously twice daily to achieve better diabetes management. Nausea, vomiting, and diarrhea were the most common adverse events reported with exenatide therapy. Exenatide is not associated with hypoglycemia, which may provide advantages over adding insulin to a sulfonylurea or metformin.
73 citations
••
TL;DR: The evidence supporting a further implementation of HbA1c testing at POC is summarized, its limitations are discussed, its recommendations are proposed and recommendations for further development are proposed.
Abstract: Diabetes is a highly prevalent disease also implicated in the development of several other serious complications like cardiovascular or renal disease. HbA1c testing is a vital step for effective diabetes management, however, given the low compliance to testing frequency and, commonly, a subsequent delay in the corresponding treatment modification, HbA1c at the point of care (POC) offers an opportunity for improvement of diabetes care. In this review, based on data from 1999 to 2016, we summarize the evidence supporting a further implementation of HbA1c testing at POC, discuss its limitations and propose recommendations for further development.
73 citations
••
TL;DR: A new long-acting insulin analog has been developed using recombinant DNA technology that has a peakless, prolonged time-action profile and is of particular relevance in children and adolescents, who are more prone to hypoglycemic episodes.
Abstract: Studies such as the Diabetes Control and Complications Trial have shown that, as in adult patients, intensive diabetes management in adolescent patients results in better glycemic control and delays the onset and slows the progression of vascular and neurological complications (1). However, a cross-sectional multinational study showed that less than one-third of the children and adolescents who underwent treatment for diabetes had adequate metabolic control (2). Providing a constant supply of basal insulin that mimics that of healthy individuals is an essential aspect of maintaining tight glycemic control in patients with type 1 diabetes. The traditional NPH insulin and ultralente basal insulin formulations do not provide a constant and reliable 24-h basal insulin supply because their duration of action is too short, and unwanted peaks of action in the night can cause nocturnal hypoglycemia (3). This is of particular relevance in children and adolescents, who are more prone to hypoglycemic episodes (4,5).
A new long-acting insulin analog has been developed using recombinant DNA technology. Insulin glargine differs from human insulin by the addition of two additional arginines on the COOH terminus of the B-chain and the replacement of an asparagine residue with glycine on the A-chain (6). The resulting molecule has a peakless, prolonged time-action profile and …
73 citations
••
TL;DR: Serum 25-OH vitamin D levels were measured in type 1 and type 2 diabetic individuals at the time of their routine visits for diabetes management, with no prior history of metabolic bone disease, vitamin D deficiency, parathyroid disease, malabsorption, or significant elevations of serum creatinine or liver enzymes.
Abstract: We report data from a pilot study examining vitamin D deficiency in type 1 and type 2 diabetes. Serum 25-OH vitamin D (25-OH-D) levels were measured in type 1 ( n = 50) and type 2 diabetic ( n = 63) individuals at the time of their routine visits for diabetes management. Patients had no prior history of metabolic bone disease, vitamin D deficiency, parathyroid disease, malabsorption, or significant elevations of serum creatinine or liver enzymes. Most subjects (74.3%) were prescribed a daily multivitamin as part of their routine diabetes care, but none were taking additional supplements. Serum was obtained during “light” (April to September) and “dark” (October to March) months. Serum 25-OH-D levels were …
73 citations